Thomas Powles

Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity.

Erythropoietin to treat anaemia in patients with head and neck cancer.

HIV and the risk of lung cancer.

Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway.

Antiapoptotic effect of growth factors in leukemia.

The changing presentation of germ cell tumours of the testis between 1983 and 2002.

Hepatocellular cancer in HIV-infected individuals: tomorrow's problem?

Does PET imaging have a role in renal cancers after all?

Non-AIDS-defining cancers in people with HIV infection: a sleeping giant?

A comparison of the platinum analogues in bladder cancer cell lines.

Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.

Germ-cell tumors.

HIV-associated Castleman's disease: from case reports to evidence.

Prostate cancer in HIV-positive individuals: what we know and what we don't.

Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over.

Novel agents for muscle-invasive and advanced urothelial cancer.

Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era.

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.

Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach.

Human immunodeficiency virus--associated renal cell carcinoma: a transatlantic case series.

Smoke and mirrors: HIV-related lung cancer.

Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.

The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.

Amplification of epidermal growth factor receptor gene in renal cell carcinoma.

The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers.

A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer.

The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe?

Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy.

Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.

A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.

Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.

The effect of sunitinib on immune subsets in metastatic clear cell renal cancer.

Castration refractory prostate cancer: cinderella finally comes to the ball.

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer.

Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.

Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.

What can molecular pathology contribute to the management of renal cell carcinoma?

Stage I nonseminomatous germ cell tumor of the testis: more questions than answers?

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.

Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.

Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial.

Sequential therapy in metastatic renal cell carcinoma: what comes next?

Whole blood stem cell re-infusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 study.

Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns.

Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.

Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy.

A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.

Neoadjuvant and adjuvant treatment of renal cell carcinoma.

An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.

Contrasting effects of sunitinib within in vivo models of metastasis.

Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy.

Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma.

The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: In response to a letter from Dr. Catalá-López.

Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation.

Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer.

The conundrum of clinical trials in adult germ-cell tumours.